Incidence and severity of anaphylactoid reactions to colloid volume substitutes.
All available colloid volume substitutes carry the risk of anaphylactoid reactions. In a multicentre prospective trial, 69 cases of anaphylactoid reactions have been observed among 200 906 infusions of colloid volume substitutes. The frequency of severe reactions (shock, cardiac and/or respiratory arrest) was 0-003% for plasma-protein solutions, 0-006% for hydroxyethyl starch, 0-008% for dextran, and 0-038% for gelatin solutions.
D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D002986:Clinical Trials as Topic; D003102:Colloids / Q000008:administration & dosage; D003911:Dextrans / Q000009:adverse effects; D005260:Female; D005780:Gelatin / Q000009:adverse effects; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D012709:Serum Albumin / Q000009:adverse effects; D013213:Starch / Q000009:adverse effects
D003102:Colloids; D003911:Dextrans; D010952:Plasma Substitutes; D012709:Serum Albumin; D005780:Gelatin; D013213:Starch